MedEdTalks - Ophthalmology: Recent Episodes
Rishi Singh, MD
MedEdTalks Ophthalmology is a continuing medical education podcast for physicians to allow them to learn while on the go and obtain CME credits. This show will focus in on ophthalmology topics, such as nAMD and Diabetic Retinopathy and includes interviews with Dr. Rishi Singh from the Cole Eye Institute, Dr. Andrew Moshfeghi from the USC Roski Eye Institute, Dr. Dilsher Dhoot from California Retina Consultants, Dr. Theodore Leng from Byers Eye Institute at Stanford, Dr. Nathan Steinle from California Retina Consultants, Dr. Nancy Holekamp from Washington University School of Medicine and Dr. Arshad Khanani from University of Nevada.
In this podcast, expert clinicians will discuss the latest information and emerging clinical trial data regarding the management of DR and DME.
https://healio.com/cme/mededtalks/ophthalmology/20241022/8-the-retina-radar-with-dr-arshad-khanani-noninvasive-treatments-for-dr-and-dme
In this podcast, expert clinicians will discuss new mechanisms of action and clinical data that supports their use in the treatment of retinal diseases.
https://healio.com/cme/mededtalks/ophthalmology/20241022/7-the-retina-radar-with-dr-arshad-khanani-going-beyond-anti-vegf
In this podcast, expert clinicians will discuss case studies focused on patient‐centered care of patients with GA.
In this podcast, expert clinicians will discuss patient‐centered GA care with a focus on approved therapies for disease management.
In this podcast, expert clinicians will discuss patient‐centered GA care with a focus on disease monitoring.
In this podcast, expert clinicians will discuss how new and emerging therapies for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) can fit into the treatment paradigm to optimize its management.
https://healio.com/cme/mededtalks/ophthalmology/20240910/6-the-retina-radar-with-dr-arshad-khanani-ga-management-in-2024-with-dr-eleonora-lad
In this podcast, expert clinicians will discuss patient‐centered GA care with a focus on diagnosis.
In this podcast, expert clinicians will discuss current and emerging treatment options that may improve outcomes for patients with diabetic retinopathy (DR).
https://healio.com/cme/mededtalks/ophthalmology/20240910/5-the-retina-radar-with-dr-arshad-khanani-dr-management-in-2024-with-dr-carl-regillo
In this podcast, expert clinicians will discuss frequently asked questions about the management of thyroid eye disease (TED).
https://healio.com/cme/mededtalks/ophthalmology/20240918/2-solving-the-ted-puzzle-management-of-thyroid-eye-disease/overview
In this podcast, expert clinicians will discuss frequently asked questions about thyroid eye disease (TED), its burden, disease course, and methods for diagnosis.
https://healio.com/cme/mededtalks/ophthalmology/20240918/1-solving-the-ted-puzzle-burden-course-and-diagnosis
In this podcast, expert clinicians will discuss the benefits and limitations of sustained delivery systems in the treatment of retinal diseases.
https://healio.com/cme/mededtalks/ophthalmology/20240801/4-the-retina-radar-with-dr-arshad-khanani-sustained-delivery
In this podcast, expert clinicians will discuss the latest information, emerging clinical trial data, and real-world studies regarding the management of DME.
https://healio.com/cme/mededtalks/ophthalmology/20240801/3-the-retina-radar-with-dr-arshad-khanani-dme-management-in-2024
In this podcast, expert clinicians will discuss new efficacy, safety, and durability data on dosing regimens, delivery systems, and emerging therapies for the treatment of neovascular age-related macular degeneration (nAMD).
https://www.healio.com/cme/mededtalks/ophthalmology/20240729/2-the-retina-radar-with-dr-arshad-khanani-namd-management-in-2024
In this podcast, expert clinicians will discuss ongoing clinical trials and the latest data regarding advances in vitreoretinal care. https://www.healio.com/cme/mededtalks/ophthalmology/20240729/1-the-retina-radar-with-dr-arshad-khanani-clinical-trials-at-the-summit-2024
In this podcast, expert clinicians will answer your questions about thyroid eye disease.
https://cme.healio.com/mededtalks/ophthalmology/20240405/3-thyroid-eye-disease-your-questions-answered
In this podcast, expert clinicians will discuss treatment approaches and monitoring parameters for thyroid eye disease.
https://cme.healio.com/mededtalks/ophthalmology/20240405/2-thyroid-eye-disease-treatment-and-monitoring
In this podcast, expert clinicians will discuss the screening and diagnosis of thyroid eye disease. https://cme.healio.com/mededtalks/ophthalmology/20240405/1-thyroid-eye-disease-screening-and-diagnosis
In this podcast, expert clinicians will review the current and emerging gene therapies for IRDs, as well as advances in drug delivery in this setting.
In this podcast, expert clinicians will discuss best practices for genetic testing and counseling for patients with IRDs, including interprofessional approaches and collaboration.
In this podcast, expert clinicians will discuss current guidelines for clinical assessment of IRDs and the importance of interprofessional collaborative care.
In this podcast, expert clinicians will discuss new research on the disease state, clinical trial designs, and emerging therapies that hold potential in the treatment of TED.
In this podcast, expert clinicians will discuss surgical procedures that can improve outcomes for patients with TED.
In this podcast, expert clinicians will discuss the benefit/risk profile of insulin-like growth factor-I receptor (IGF-1R) therapy in the treatment of TED.
In this podcast, expert clinicians will discuss real-world evidence regarding the safety and efficacy of current medical treatments for TED.
In this podcast, expert clinicians will discuss advanced techniques and technology for guiding refractive surgery to reduce complications and achieve better visual outcomes.
In this podcast, expert clinicians will discuss advances in presurgical/surgical diagnostics and intraoperative guidance systems and their impact on improved refractive outcomes.
In this podcast, expert clinicians will discuss new evidence and real-world studies regarding the management of diabetic macular edema.
In this podcast, expert clinicians will discuss advances in biometry and IOL platforms.
In this podcast, expert clinicians will discuss the latest information on phacoemulsification, including the use of fluidics, ultrasound, phacodynamics, advanced techniques, and instrumentation.
In this podcast, expert clinicians will discuss the management of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
In this podcast, expert clinicians will discuss surgical techniques in cataract removal.
In this podcast, expert clinicians with discuss the latest information on the digital integration of medical and surgical eye care.
In this podcast, expert clinicians will discuss ongoing clinical trials and the latest data in vitreoretinal care from the Clinical Trials Summit.
In this podcast, expert faculty will discuss the management of diabetic retinopathy (DR).
In this podcast, expert clinicians will discuss long-acting injectables in RVO management.
In this podcast, expert clinicians will discuss long-acting injectables in DME management.
In this podcast, expert clinicians will discuss long-acting injectables in nAMD management.
In this educational activity, faculty discuss current and emerging strategies for diagnosis and management of meibomian gland dysfunction and associated conditions.
In this educational activity, faculty discuss recent developments in ocular surface disease presented at the Fall 2022 academic conferences.
In this podcast, expert clinicians will discuss current and future approaches for the management of patients with uveitis.
In this podcast, expert clinicians will discuss the utilization of surgery in the management of patients with retinal diseases.
In this podcast, expert clinicians will discuss the utilization of imaging in patients with retinal diseases.
In this podcast, expert clinicians will discuss current and future approaches for the management of patients with retinal vein occlusion.
In this podcast, expert clinicians will discuss current and future approaches for the management of patients with neovascular age-related macular degeneration, dry age-related macular degeneration, and geographic atrophy.
In this podcast, expert clinicians will discuss current and future approaches for the management of patients with diabetic eye disease.
The angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering the treatment burden. In this podcast, Dr. Carl Regillo and Dr. Nancy Holekamp discuss the efficacy and safety of therapies targeting Ang-2 in DME.
The angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering the treatment burden. In this podcast, Dr. Carl Regillo and Dr. Arshad Khanani discuss the efficacy and safety of therapies targeting Ang-2 in nAMD.
The angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering the treatment burden. In this podcast, Dr. Carl Regillo and Dr. Judy Kim discuss the Tie2 pathway and its role in the pathophysiology of retinal vascular diseases.
Steven Ferrucci, OD, provides an overview of the CE-certified ePublication, Retinal Disease Digest: Opportunities for Optometrists Volume 1, Issue 4.
Rishi P. Singh, MD, provides an overview of the CE-certified ePublication, Retinal Disease Digest: Opportunities for Optometrists Volume 1, Issue 3.
Steven Ferrucci, OD, provides an overview of the CE-certified ePublication, Retinal Disease Digest: Opportunities for Optometrists Volume 1, Issue 2.
Rishi P. Singh, MD, provides an overview of the CE-certified ePublication, Retinal Disease Digest: Opportunities for Optometrists Volume 1, Issue 1.
In this podcast, expert clinicians will discuss best practices for reducing ocular toxicities in myeloma patients through the multidisciplinary team.
In this podcast, expert clinicians will discuss strategies to mitigate and manage ocular toxicities related to multiple myeloma therapy.
In this podcast, expert clinicians will discuss the frequency and identification of ocular toxicities of patients on myeloma therapy.
In this podcast, expert clinicians will discuss the mechanisms behind ocular toxicities that have been associated with antibody drug conjugates used for cancer treatment.
This educational activity will review best practices regarding the use of gel stents in the treatment of glaucoma.
In this podcast, John Samples, MD, and Brian Francis, MD, discuss the current and evolving role of optical coherence tomography angiography in the management of glaucoma.
In this podcast, John Samples, MD, and Michael Giovigno, MD, review best practices for the use of cyclophotocoagulation in the management of glaucoma.
In this podcast, John R. Samples, MD, and Russell Swan, MD, discuss the relevance of cerebrospinal fluid pressure in the management of glaucoma.
This educational activity will review best practices in the management of patients with glaucoma.
Recap with Dr. Rishi Singh: An Overview of Intravitreal Interventions Volume 10, Issue 4
Recap with Dr. Rishi Singh: An Overview of Intravitreal Interventions Volume 10, Issue 3
Recap with Dr. Rishi Singh: An Overview of Intravitreal Interventions Volume 10, Issue 2
This educational podcast will review the use of combination therapy, new drug formulations, and procedures to improve outcomes for patients with ocular surface disease.
In this educational podcast, experts discuss emerging therapies for their ability to improve outcomes in patients with ocular surface disease. Faculty also review the safety and efficacy data to support new and emerging treatment options for OSD.
This educational podcast will review important considerations for the diagnosis and management of ocular surface disease (OSD) in special patient populations. Faculty will provide pearls for preventing and managing OSD in individuals at elevated risk, including those undergoing ocular surgery, those with glaucoma or diabetes, as well as individuals on medications known to disrupt the ocular surface.
Recap with Dr. Rishi Singh: An Overview of Intravitreal Interventions, Volume, 10, Issue 1
In this podcast, expert clinicians will discuss best practices regarding the use of Port Delivery System with ranibizumab.
In this podcast, expert clinicians will discuss achieving vascular stability through inhibition of Ang-2.
To obtain CME credit, go here: https://tinyurl.com/y58538ef
In this podcast, expert clinicians will discuss emerging gene therapies for AMD and DME.
To obtain CME credit, go here: https://tinyurl.com/yusxpn44
In this podcast, expert clinicians will discuss emerging delivery system devices in neovascular retinal disease.
To obtain CME credit, please go here: https://tinyurl.com/thma9fwp
Retinal vein occlusions (RVOs) are the second most common retinal vascular disorder after diabetic retinopathy. The early and accurate diagnosis of RVO is paramount so that therapy can be initiated in a timely manner to prevent vision decline. Newer imaging technologies integrated into current diagnostic algorithms are aiding in the diagnosis of RVO and guiding therapy. Further, significant visual and anatomic improvements have been demonstrated with anti-vascular endothelial growth factor (VEGF) therapies in patients with central or branch RVO-related macular edema, and refinement of treatment protocols have the potential to further enhance outcomes as well as reduce treatment burden. In this curbside consult, Drs. Carl Regillo and Christina Weng assess the effect of treating RVO early in its course for the improvement of visual outcomes.
Retinal vein occlusions (RVOs) are the second most common retinal vascular disorder after diabetic retinopathy. The early and accurate diagnosis of RVO is paramount so that therapy can be initiated in a timely manner to prevent vision decline. Newer imaging technologies integrated into current diagnostic algorithms are aiding in the diagnosis of RVO and guiding therapy. Further, significant visual and anatomic improvements have been demonstrated with anti-vascular endothelial growth factor (VEGF) therapies in patients with central or branch RVO-related macular edema, and refinement of treatment protocols have the potential to further enhance outcomes as well as reduce treatment burden. In this curbside consult, Drs. Carl Regillo and Christina Weng discuss the current use of imaging and biomarkers in the diagnosis as well as prognosis of RVO.
Retinal vein occlusions (RVOs) are the second most common retinal vascular disorder after diabetic retinopathy. The early and accurate diagnosis of RVO is paramount so that therapy can be initiated in a timely manner to prevent vision decline. Newer imaging technologies integrated into current diagnostic algorithms are aiding in the diagnosis of RVO and guiding therapy. Further, significant visual and anatomic improvements have been demonstrated with anti-vascular endothelial growth factor (VEGF) therapies in patients with central or branch RVO-related macular edema, and refinement of treatment protocols have the potential to further enhance outcomes as well as reduce treatment burden. In this curbside consult, Drs. Carl Regillo and David Eichenbaum examine innovations in imaging that can improve the monitoring of treatment response in patients with RVO.
Retinal vein occlusions (RVOs) are the second most common retinal vascular disorder after diabetic retinopathy. The early and accurate diagnosis of RVO is paramount so that therapy can be initiated in a timely manner to prevent vision decline. Newer imaging technologies integrated into current diagnostic algorithms are aiding in the diagnosis of RVO and guiding therapy. Further, significant visual and anatomic improvements have been demonstrated with anti-vascular endothelial growth factor (VEGF) therapies in patients with central or branch RVO-related macular edema, and refinement of treatment protocols have the potential to further enhance outcomes as well as reduce treatment burden. In this curbside consult, Drs. Carl Regillo and David Eichenbaum discuss how advances in the treatment of RVO achieved in clinical trials can be applied to real-world practice.
In this podcast, expert clinicians will discuss diagnosing and managing a challenging case of neuromyelitis optica spectrum disorder (NMOSD).
In this podcast, expert clinicians will discuss clinical trial data of biologics used in neuromyelitis optica spectrum disorder (NMOSD).
In this podcast, expert clinicians will discuss the mechanisms of action of biologics used in neuromyelitis optica spectrum disorder (NMOSD).
In this podcast, expert clinicians will discuss best practices in diagnosing neuromyelitis optica spectrum disorder (NMOSD).
In this podcast, expert clinicians will discuss a challenging case in the treatment of neurotrophic keratitis.
In this podcast, expert clinicians will discuss a challenging case in the staging and diagnosis of neurotrophic keratitis.
In this podcast, expert clinicians will discuss different treatment options for neurotrophic keratitis.
In this podcast, expert clinicians will discuss pathophysiology, diagnosis, and staging of neurotrophic keratitis.
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence due to treatment burden remains a significant problem. Continuing advances in the refinement of dosing frequency protocols, as well as the development of therapies and devices that promise to extend dosing intervals, have the potential to overcome treatment burden, further enhancing long-term visual outcomes. Within this 4-part podcast series, experts in the field discuss current therapy dosing schedules and their impact on visual outcomes and patient adherence, assess novel mechanisms of action of emerging therapies that have the potential to improve visual acuity, as well as evaluate new and emerging therapeutic and dosing options that have the potential to reduce treatment burden in patients with nAMD.
Transcription: https://tinyurl.com/Ophthalmology3
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence due to treatment burden remains a significant problem. Continuing advances in the refinement of dosing frequency protocols, as well as the development of therapies and devices that promise to extend dosing intervals, have the potential to overcome treatment burden, further enhancing long-term visual outcomes. In this podcast, Dr. Arshad Khanani and Dr. Peter Kaiser interpret the latest clinical trial data of new and emerging treatments for nAMD.
Transcripts: https://tinyurl.com/Ophthalmology3-4
For CME Credit, click here: https://tinyurl.com/Ophthalmology3-4a
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence due to treatment burden remains a significant problem. Continuing advances in the refinement of dosing frequency protocols, as well as the development of therapies and devices that promise to extend dosing intervals, have the potential to overcome treatment burden, further enhancing long-term visual outcomes. In this podcast, Dr. Arshad Khanani and Dr. Nancy Holekamp discuss dosing schedules for emerging agents in the treatment of nAMD that require less frequent dosing than standard anti-VEGF therapies.
Transcription: https://tinyurl.com/Ophthalmology3-3a
For CME Credit, complete activity here: https://tinyurl.com/Ophth3-3a
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence due to treatment burden remains a significant problem. Continuing advances in the refinement of dosing frequency protocols, as well as the development of therapies and devices that promise to extend dosing intervals, have the potential to overcome treatment burden, further enhancing long-term visual outcomes. In this podcast, Dr. Arshad Khanani and Dr. Peter Kaiser discuss novel mechanisms beyond anti-VEGF for the treatment of nAMD.
Transcription: https://tinyurl.com/Ophthalmology3-2a
For CME Credit, complete activity here: https://tinyurl.com/Ophth3-2a
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence due to treatment burden remains a significant problem. Continuing advances in the refinement of dosing frequency protocols, as well as the development of therapies and devices that promise to extend dosing intervals, have the potential to overcome treatment burden, further enhancing long-term visual outcomes. In this podcast, Dr. Arshad Khanani and Dr. Nancy Holekamp discuss dosing schedules for current anti-VEGF agents used in the treatment of nAMD.
Transcript: https://tinyurl.com/Ophthalmology3-1a
For CME credit, complete activity here: https://tinyurl.com/Ophth3-1a
The integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patient adherence. However, suboptimal responses to therapy along with loss of patient adherence from treatment burden has defined a need for the development of novel treatments and sustained delivery options for the management of neovascular retinal diseases. In this podcast, Dr. Carl Regillo and Dr. Dante Pieramici discuss the effect of subretinal fluid on visual outcomes in neovascular age-related macular degeneration.
The integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patient adherence. However, suboptimal responses to therapy along with loss of patient adherence from treatment burden has defined a need for the development of novel treatments and sustained delivery options for the management of neovascular retinal diseases. In this podcast, Dr. Carl Regillo and Dr. Dante Pieramici discuss the potential effects of sustained vascular endothelial growth factor inhibition in neovascular retinal disease.
The integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patient adherence. However, suboptimal responses to therapy along with loss of patient adherence from treatment burden has defined a need for the development of novel treatments and sustained delivery options for the management of neovascular retinal diseases. In this podcast, Dr. Carl Regillo and Dr. Charles Wykoff discuss effective treatment interval extensions in neovascular retinal disease.
The integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patient adherence. However, suboptimal responses to therapy along with loss of patient adherence from treatment burden has defined a need for the development of novel treatments and sustained delivery options for the management of neovascular retinal diseases. In this podcast, Dr. Carl Regillo and Dr. Jeffrey Heier discuss inhibition of angiopoietin-2 and its potential effect on current treatment paradigms for the management of diabetic macular edema.
The integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patient adherence. However, suboptimal responses to therapy along with loss of patient adherence from treatment burden has defined a need for the development of novel treatments and sustained delivery options for the management of neovascular retinal diseases. In this podcast, Dr. Carl Regillo and Dr. Jeffrey Heier discuss inhibition of angiopoietin-2 and its potential effect on current treatment paradigms for the management of neovascular age-related macular degeneration.
The integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patient adherence. However, suboptimal responses to therapy along with loss of patient adherence from treatment burden has defined a need for the development of novel treatments and sustained delivery options for the management of neovascular retinal diseases. In this podcast, Dr. Carl Regillo and Dr. Charles Wykoff discuss emerging drug delivery systems for the management of neovascular retinal disease.
In this MedEdTalks micro-CE podcast, Rishi P. Singh, MD, and Arshad M. Khanani, MD, MA, discuss new findings about emerging therapies that target the angiopoietin/Tie2 pathway that may improve the treatment of neovascular retinal diseases.
Transcript: https://bit.ly/38jWicU
To obtain CME Credit, please go here: https://bit.ly/2nBqmhq
In this MedEdTalks micro-CE podcast, Rishi P. Singh, MD, and Nancy M. Holekamp, MD, discuss delivery systems for neovascular retinal diseases, with a particular focus on age-related macular degeneration.
Transcript: https://bit.ly/2PqSj5P
To obtain CME credit, please go here: https://bit.ly/2mNmJVt
In this MedEdTalks micro-CE podcast, Rishi P. Singh, MD, and Nathan C. Steinle, MD, discuss dosing strategies in patients with neovascular age-related macular degeneration (AMD) to help improve patient outcomes.
Transcript: https://bit.ly/2DZw9SC
To obtain CME credit, please go here: https://bit.ly/2ombOmh
In this MedEdTalks micro-CE podcast, Rishi P. Singh, MD, and Theodore Leng MD, MS, discuss the burden of treatment on patients with neovascular age-related macular degeneration (AMD) and strategies for overcoming barriers to treatment.
Transcript: https://bit.ly/2YB3q0e
To obtain CME Credit, please go here: https://bit.ly/2ojxBec
In this MedEdTalks micro-CE podcast, Rishi P. Singh, MD, and Dilsher S. Dhoot, MD, discuss current barriers to care of patients with neovascular age-related macular degeneration (AMD) and other management considerations for providers.
Transcript: https://bit.ly/2RL41uX
To obtain CME Credit, please go here: https://bit.ly/2mJfo9s
In this MedEdTalks micro-CE podcast, Rishi P. Singh, MD, and Andrew A. Moshfeghi, MD, MBA, will discuss current insights and the evidence-based use of anti-vascular epithelial growth factor (VEGF) in diabetic retinopathy.
Transcript: https://bit.ly/3542h3r
To obtain CME credit, please go here: https://bit.ly/2ojW0QQ
In this podcast series Dr. Rishi Singh will be talking with:
- Dr. Andrew Moshfeghi on Current Insights into Anti-VEGF use in Diabetic Retinopathy;
- Dr. Dilsher Dhoot on how to address the treatment burden in nAMD as a provider;
- Dr. Ted Leng on how to address the treatment burden in nAMD with patients;
- Dr. Nathan Steinle on real world applications for dosing strategies in nAMD;
- Dr. Nancy Holekamp on drug delivery in neovascular retinal disease; and with
- Dr. Arshad Khanani on targeting treatment in neovascular retinal disease
We encourage you to take 12 to 15 minutes out of your day to hear these updates on neovascular retinal diseases